Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
Humans
Tuberculosis, Multidrug-Resistant
/ drug therapy
World Health Organization
Antitubercular Agents
/ therapeutic use
Europe
Linezolid
/ therapeutic use
Rifampin
/ therapeutic use
Moxifloxacin
/ therapeutic use
Diarylquinolines
/ therapeutic use
Nitroimidazoles
/ therapeutic use
Mycobacterium tuberculosis
/ drug effects
Health Services Accessibility
Europe
MDR/RR-TB
access
drug availability
pretomanid
tuberculosis
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
26
4
2024
Statut:
ppublish
Résumé
The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.
Identifiants
pubmed: 38666403
doi: 10.2807/1560-7917.ES.2024.29.17.2400211
doi:
Substances chimiques
Antitubercular Agents
0
Linezolid
ISQ9I6J12J
Rifampin
VJT6J7R4TR
Moxifloxacin
U188XYD42P
bedaquiline
78846I289Y
Diarylquinolines
0
pretomanid
0
Nitroimidazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM